### Eli Lilly's New Insulin Pricing Policy and Its Benefits Eli Lilly, a major drug manufacturer, has announced significant price reductions for some of its most commonly used insulin products. Here are the key points: 1. **Price Reduction**: Eli Lilly is cutting the price of its insulin products by 70%. This is a substantial reduction that will make insulin more affordable for many patients. 2. **Out-of-Pocket Cost Cap**: The company will cap out-of-pocket costs at $35 for many patients. This cap applies to people with private health insurance and those without health benefits who can download a savings card to get the same price. 3. **Immediate Implementation**: The $35 cap is effective immediately at many retail pharmacies for people with private health insurance. This means that patients can start benefiting from the reduced costs right away. 4. **New Products and Discounts**: Starting in April, Eli Lilly will sell a biosimilar version of its slow-acting injectable Lantus insulin pens for $92 per five-pack of KwikPens, a 78% discount. In May, the price for its nonbranded mealtime insulin Humalog will be reduced to $25 a vial. By the end of the year, the price of its most commonly prescribed insulin, branded Humalog, will be reduced by 70%. 5. **Impact on Patients**: These price cuts are expected to make a significant difference for Americans with diabetes. Rising insulin prices have forced some people to ration their medicine, skipping doses or delaying prescription refills. The new pricing policy aims to alleviate this burden. 6. **Legislative Context**: Last year, Congress passed legislation to cap insulin costs at $35 for people insured by Medicare. However, similar caps for younger people and those with private insurance were not passed. Eli Lilly's new policy helps fill this gap. 7. **Support from Health Organizations**: The American Diabetes Association has applauded Eli Lilly for this initiative and encourages other insulin manufacturers to follow suit. Overall, Eli Lilly's new insulin pricing policy is a significant step towards making diabetes management more affordable and accessible for millions of Americans.